Q1 Earnings Estimate for Korro Bio Issued By HC Wainwright

Korro Bio, Inc. (NASDAQ:KRRO) – Investment analysts at HC Wainwright reduced their Q1 2025 earnings per share (EPS) estimates for Korro Bio in a note issued to investors on Thursday, March 20th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($2.54) per share for the quarter, down from their previous forecast of ($2.45). HC Wainwright currently has a “Buy” rating and a $115.00 target price on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($9.52) per share. HC Wainwright also issued estimates for Korro Bio’s Q2 2025 earnings at ($2.67) EPS, Q3 2025 earnings at ($2.82) EPS, Q4 2025 earnings at ($2.97) EPS and FY2025 earnings at ($11.00) EPS.

Korro Bio (NASDAQ:KRRO) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($2.26) EPS for the quarter, beating analysts’ consensus estimates of ($2.33) by $0.07. The company had revenue of $2.27 million during the quarter.

Several other equities research analysts have also commented on the stock. Oppenheimer initiated coverage on shares of Korro Bio in a research note on Friday, January 10th. They issued an “outperform” rating and a $155.00 price objective for the company. Royal Bank of Canada decreased their price target on Korro Bio from $105.00 to $95.00 and set an “outperform” rating for the company in a research report on Wednesday, March 19th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $142.57.

Korro Bio Price Performance

Shares of KRRO stock opened at $20.38 on Monday. The firm has a 50-day moving average of $29.27 and a 200-day moving average of $41.09. Korro Bio has a one year low of $18.50 and a one year high of $98.00. The company has a market cap of $191.35 million, a P/E ratio of -2.17 and a beta of 2.13.

Institutional Investors Weigh In On Korro Bio

A number of hedge funds have recently modified their holdings of KRRO. KLP Kapitalforvaltning AS bought a new stake in shares of Korro Bio in the fourth quarter valued at $53,000. Quest Partners LLC increased its holdings in Korro Bio by 172.1% in the 3rd quarter. Quest Partners LLC now owns 1,777 shares of the company’s stock worth $59,000 after acquiring an additional 1,124 shares during the last quarter. AlphaQuest LLC raised its stake in Korro Bio by 23.2% in the 4th quarter. AlphaQuest LLC now owns 2,189 shares of the company’s stock valued at $83,000 after acquiring an additional 412 shares during the period. Brown Brothers Harriman & Co. lifted its holdings in Korro Bio by 251.0% during the third quarter. Brown Brothers Harriman & Co. now owns 2,854 shares of the company’s stock valued at $95,000 after purchasing an additional 2,041 shares during the last quarter. Finally, Vestcor Inc bought a new position in Korro Bio during the third quarter worth about $100,000. Institutional investors own 13.18% of the company’s stock.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).